Pursuit Vascular is developing a family of products based on its patent-pending ClearGuard™ platform technology. The first product targets infections associated with hemodialysis catheters.
Dialysis catheter patients experience an average of 1.5 catheter-related infections per year. These infections greatly impact patient morbidity and mortality, resulting in approximately 23,000 deaths in the US and costing Medicare an estimated $1.5B each year.
Antimicrobial fluid locks have been clinically proven to reduce infection rates by 85%
Pursuit Vascular's innovative ClearGuard™ technology is intended to capture all the benefits of antimicrobials without the associated issues. Each product is being designed to safely and cost-effectively prevent infection, resulting in substantial savings to the global healthcare system.
